Utility of islet autoantibodies as enrichment biomarkers in type 1 diabetes clinical studies: a viewpoint from the FDA.

Penzenstadler, Justin; Earp, Justin C; Wood Heickman, Lauren K; Pluchino, Kristen

Penzenstadler, Justin; Earp, Justin C; Wood Heickman, Lauren K; Pluchino, Kristen.

Afiliação

Penzenstadler J; Division of Diabetes, Lipid Disorders, and Obesity, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA. justin.penzenstadler@fda.hhs.gov.
Earp JC; Division of Pharmacometrics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Wood Heickman LK; Division of Diabetes, Lipid Disorders, and Obesity, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Pluchino K; Division of Diabetes, Lipid Disorders, and Obesity, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.

Diabetologia ; 66(3): 603-604, 2023 03.

Article em En | MEDLINE | ID: mdl-36542112

Assuntos

Diabetes Mellitus Tipo 1; Ilhotas Pancreáticas; Humanos; Autoanticorpos; Biomarcadores; Glutamato Descarboxilase

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ilhotas Pancreáticas / Diabetes Mellitus Tipo 1 Limite: Humans Idioma: En Revista: Diabetologia Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google